Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketoprofen
Drug ID BADD_D01231
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indications and Usage For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Marketing Status approved; vet_approved
ATC Code M01AE03; M02AA10
DrugBank ID DB01009
KEGG ID D00132
MeSH ID D007660
PubChem ID 3825
TTD Drug ID D0W9WF
NDC Product Code 51604-0011; 71574-122; 0276-0506; 43235-0010; 51927-0304; 76465-0001; 12660-0006; 38779-3039; 49452-3924; 51927-0231; 45865-485; 0276-0504; 51927-0025; 51927-0057; 68981-031; 63275-9996; 82348-102; 63187-018; 38779-0078; 0378-8200; 51552-0307; 51927-0299; 79572-019
UNII 90Y4QC304K
Synonyms Ketoprofen | Benzoylhydratropic Acid | 2-(3-Benzoylphenyl)propionic Acid | Profenid | Alrheumum | Orudis | 19,583 RP | RP, 19,583 | RP-19583 | RP 19583 | RP19583 | Alrheumat
Chemical Information
Molecular Formula C16H14O3
CAS Registry Number 22071-15-4
SMILES CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Swelling08.01.03.0150.002240%Not Available
Swelling face23.04.01.018; 08.01.03.100; 10.01.05.0180.004481%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.007841%
Tachycardia02.03.02.0070.010082%Not Available
Tenderness08.01.08.0050.002240%Not Available
Tension19.06.02.005--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat tightness22.12.03.031; 19.01.02.0050.005601%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.004481%Not Available
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.0150.004481%
Tremor17.01.06.0020.005601%
Tricuspid valve incompetence02.07.05.0010.002240%Not Available
Type I hypersensitivity10.01.03.0060.004481%Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.0010.045255%
Vascular pain24.03.02.0260.002240%Not Available
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.0110.002240%Not Available
Vertigo17.02.12.002; 04.04.01.0030.002240%
Visual impairment06.02.10.0130.002240%Not Available
Vomiting07.01.07.0030.030245%
Water intoxication14.05.06.004; 05.03.03.003; 19.07.03.0040.002240%Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.002240%
Tubulointerstitial nephritis20.05.02.0020.004481%Not Available
Joint range of motion decreased15.01.02.0060.002240%
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.005; 11.07.01.018; 10.01.01.0340.003361%Not Available
Hypoacusis04.02.01.006--
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene